Movent

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Movent

What is Movent?

Property Description
Active ingredient Ambroxol hydrochloride
Form Tablets, Syrups, Solutions for Inhalation
Pharmacological class Mucoactive agent, Secretolytic
General purpose Facilitates mucus clearance and eases congestion
Origin Synthetic derivative of Bromhexine

What Type of Medicine is Movent?

Movent is a pharmaceutical preparation whose active compound, Ambroxol hydrochloride, classifies it as a mucoactive agent and, more specifically, a secretolytic and expectorant drug. This classification indicates its primary function is to normalize the pathological viscosity and flow of respiratory secretions. The substance Ambroxol is recognized as a synthetic derivative of the compound Bromhexine, reflecting an established chemical lineage within cough and cold pharmacology. Ambroxol is formally categorized under the group R05CB06 for mucolytics. The drug entity is available across multiple high-level dosage forms, including oral solid forms, liquid syrups, and specialized nebulized solutions.


Understanding the Composition and Forms of Movent

Movent is a single-ingredient product, containing only Ambroxol hydrochloride as the compound responsible for its therapeutic effect on the airways. As a multi-formulation drug, it can be administered through different routes of administration, primarily oral or via inhalation, depending on the prescribed formulation. Ambroxol is effective in facilitating the removal of secretions in acute and chronic bronchopulmonary diseases. The versatility of its pharmaceutical preparation allows it to be introduced into the body either systemically through the digestive tract or directly into the respiratory system for a more localized effect, which is often used for severe, stubborn congestion. The high-level composition consists of the active ingredient Ambroxol combined with an appropriate pharmaceutical vehicle, such as an aqueous solvent for liquid preparations.


The Core Purpose of Movent: Improving Airway Clearance

The general purpose of Movent is to facilitate the efficient clearance of mucus and secretions from the lungs and bronchial tubes, thereby relieving chest congestion associated with conditions that produce excess phlegm. It achieves this by performing a dual action: breaking down the structural fibers of thick, sticky mucus (secretolytic action) while simultaneously stimulating the production of essential pulmonary surfactant. This combined mechanism is clinically recognized for its ability to restore the natural mucociliary transport system, promoting sustained respiratory comfort.

What side effects are possible with Movent?

Possible side effects and safety information for Movent

This section summarizes the officially documented adverse reactions and safety considerations for this medicine, based on regulatory filings. This information is intended for educational purposes and should not be used as a substitute for professional medical consultation.


Serious and Clinically Significant Adverse Reactions

The most serious safety concerns identified in the regulatory documents are those related to the gastrointestinal system. Movent is strictly contraindicated for patients who have, or are at high risk of, bowel obstruction (gastrointestinal blockage) or gastrointestinal perforation (a hole developing in the wall of the gut), including those with cancer who are at high risk of perforation. Use of the medicine may also need to be restricted for patients with moderately to severely reduced kidney function or those taking certain other medicines that increase the drug's exposure in the body.

Common Adverse Reactions

Clinical trials documented the following as the most common adverse reactions, which may affect more than 5 in 100 people. These effects are generally mild to moderate, often occur early in treatment, and tend to improve with continued use:

  • Abdominal pain (stomach ache)
  • Diarrhea
  • Nausea (feeling sick)
  • Headache
  • Flatulence (passing wind)

Safety Monitoring and Restrictions

Regulatory Basis: The safety profile is defined through the assessment of European regulatory authority documents.

Population-Specific Notes: A lower starting dose may be necessary for patients with impaired kidney function. The medicine must not be used concurrently with certain medications that significantly affect its metabolism.

Safety Context: The overall official safety profile establishes that the main risks are concentrated in the gastrointestinal tract, especially regarding the risk of obstruction or perforation in susceptible individuals, necessitating careful screening and restriction of use in certain high-risk populations.

Overdose and Emergency Response

The official regulatory profile for Movent (Ambroxol hydrochloride) overdose is based on documented clinical experience, which indicates that symptoms are typically an exaggeration of known undesirable effects. These manifestations primarily affect the gastrointestinal system and include nausea, vomiting, diarrhea, abdominal pain, and heartburn. Mild central nervous system effects such as short-term restlessness have also been noted. Regulatory texts indicate that severe signs of intoxication are not commonly recorded in non-extreme clinical overdose scenarios. However, hypotension (a drop in blood pressure) is considered a potential serious outcome of extreme overdosage, based on preclinical data.

Due to the absence of a known specific antidote, overdose management is described as being mainly symptomatic and supportive. Acute procedural interventions, such as gastric lavage or induced vomiting, are generally not indicated and are reserved by regulators for only the most extreme overdosage cases. A patient who has taken a dose exceeding the recommendation must seek immediate medical consultation or emergency medical treatment. This action is mandated by regulatory authorities to ensure necessary patient observation and care, even if no acute poisoning symptoms have been observed initially.

Therapeutic Uses of Movent

Quick Facts: Movent Nasal Spray

  • Relieves Symptoms of Allergic Rhinitis: Helps to manage nasal symptoms associated with seasonal and year-round allergies.
  • Addresses Nasal Congestion: Works to lessen a blocked or stuffy nose.
  • Management of Nasal Polyps: Indicated for use in managing nasal growths.

What Movent Treats: Main Uses and Benefits

Movent Nasal Spray is a prescribed medication utilized for the local management of certain nasal conditions. The therapeutic focus of this treatment centers on diminishing localized symptoms associated with inflammation.

Primary Indications

The medication is used to mitigate the signs and symptoms of allergic rhinitis, often referred to as hay fever. This includes supporting the relief of nasal discomfort, such as sneezing, runny nose, and itching in the nasal passages, which are common manifestations of seasonal and perennial allergies. It is an appropriate component of a strategy to help maintain comfort during peak allergy periods.

Additional Uses

In addition to allergic symptom relief, Movent Nasal Spray is clinically indicated for the management of nasal polyps in adult patients. Nasal polyps are non-cancerous growths that can lead to difficulties with breathing through the nose. Use of the spray contributes to lessening the size of these growths, which may support improved nasal airflow. Furthermore, it is a suitable option for the therapeutic management of nasal congestion (a blocked nose) generally associated with inflammation.

Eligibility and Restrictions for Use

Who Can and Cannot Use Movent? (Official Regulatory Information)

Eligibility Scope

Movent is contraindicated and must not be used by specific populations. This includes patients with known hypersensitivity to Ambroxol hydrochloride or its excipients, and children under 2 years of age for oral formulations, where use is prohibited due to physiological risks. Additionally, the medicine is contraindicated in patients with rare hereditary disorders such as fructose or galactose intolerance if the specific product contains relevant excipients.

Age-related eligibility is established for adults, adolescents over 12, and children from 2 to 12 years.

Eligibility-Related Restrictions

Use is not recommended for women in the first trimester of pregnancy and those who are breastfeeding, as the substance is known to be excreted in breast milk. Conditional use and medical supervision are required for patients with severe renal impairment or severe hepatic impairment, where a metabolite accumulation is expected. Caution is also advised for patients with a history of peptic or duodenal ulcers or compromised airway motility.

Connection to the Overall Eligibility Profile

Regulatory documents define eligibility through absolute prohibitions based on allergy and age, while stipulating conditional use or caution for populations with compromised organ function or specific reproductive status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Movent (Ambroxol hydrochloride) identifies specific interactions with certain medicinal products and constraints related to existing health conditions. These documented patterns fall into two main categories: pharmacodynamic risks and altered drug exposure.

Interacting Substance/Condition Regulatory Description of Interaction
Antitussive Medicines (Cough Suppressants) Strict Restriction: Co-administration is prohibited or strongly advised against in regulatory documents. This restriction stems from a pharmacodynamic effect: the suppression of the cough reflex can cause the dangerous retention of liquefied bronchial secretions, potentially leading to airway congestion.
Antibiotics (e.g., Amoxicillin, Cefuroxime) Altered Local Exposure: Co-administration with Movent results in a formally documented increase in the concentration of the antibiotic within the bronchopulmonary secretions. This effect has been specifically confirmed for medicines including Amoxicillin, Cefuroxime, Erythromycin, and Doxycycline.

Interaction-Related Clearance Constraints

Interaction risk factors are heightened in certain populations due to the drug’s elimination pathways. In cases of severe hepatic impairment, regulatory information notes a corresponding decreased clearance of the active ingredient itself. For individuals with severe renal impairment, there is an expectation of accumulation of Ambroxol metabolites because of the reduced capacity for kidney elimination.

Mechanism of Action

How Movent Works

The physiological actions of Ambroxol hydrochloride are driven by a triple-action mechanism that modulates both the physical properties of respiratory secretions and sensory nerve excitability.


Modulation of Mucus Structure (Secretolytic Action)

The core mechanism involves the secretolytic action, where the molecule directly engages the structural components of high-viscosity bronchial secretions. It achieves this by the depolymerization and cleavage of the long chains of acidic mucopolysaccharide fibers, which determines secretion viscosity. This chemical action reduces the structural integrity of the secretions, directly leading to a lowering of viscosity and elasticity, which supports the movement of secretions.


Enhancement of Surfactant and Mucociliary Transport

This domain involves cellular regulation, specifically the stimulation of Type II pneumocytes to increase the synthesis and release of pulmonary surfactant . The surfactant reduces the adhesion of mucus to the bronchial walls and lowers the surface tension of the fluid. This action supports the function of the mucociliary transport system, the primary physiological mechanism for the clearance of secretions.


Peripheral Stabilization of Sensory Nerves

A separate physiological consequence is the localized membrane-stabilizing effect on sensory nerve endings. Ambroxol acts as a concentration-dependent inhibitor of voltage-gated sodium ( Na^+) channels located in the upper respiratory tract. By blocking the flow of ions, this action reduces the excitability of these nerves. This mechanism leads to a reduction in the detection of irritant stimuli and afferent signaling from the affected peripheral areas, which modulates the transmission of local sensory input.

Dosage and Administration Information

How to Use Movent: Administration Guidelines

Movent (Ambroxol hydrochloride) is utilized through several administration routes, primarily oral (tablets, syrups, capsules), inhalation (nebulized solution), and parenteral (Intravenous, Intramuscular, or Subcutaneous) injection in supervised settings.

Standard Dosing and Frequency

Prescribing information for standard oral formulations outlines a biphasic dosing regimen for adults. The usual starting dose is 30 mg taken three times daily (90 mg/day), typically for the initial 2 to 3 days. This transitions to a maintenance dose of 30 mg twice daily (60 mg/day). The maximum recommended daily intake is generally limited to 120 mg. Alternatively, the prolonged-release capsule formulation is intended for administration as 75 mg once daily.

For oral administration, the medicine can be taken with or without food; however, consuming it after meals may help to minimize potential gastrointestinal discomfort. Tablets should be taken with sufficient fluids. In the event of a missed dose, the next scheduled dose should be taken at the regular time, and a double dose must not be taken to compensate.

Duration and Special Conditions

For acute use, the duration of treatment is typically constrained, and it should not exceed 4 to 5 days without consulting a health professional. Furthermore, the 75 mg prolonged-release capsules must be swallowed whole and must not be crushed or chewed, as this alters the intended drug release.

Population-Specific Instructions state that patients with severe renal or hepatic impairment require a reduction in the dosage or an extension of the time interval between administrations. Pediatric dosing is strictly weight- or age-dependent, utilizing the oral syrup form.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the clinical research that evaluated the compound's properties and its potential findings. The summary is based strictly on data from published clinical trials.


Primary Research Focus

Research has evaluated whether the compound is associated with changes in pain and assessed the time frame of reported changes related to targeting inflammation. Safety was evaluated in clinical trials under specific conditions.

  • Mechanism of Action: Studies evaluated the compound’s interaction with specific inflammatory markers in models of chronic pain. Data was collected in preclinical and human phases to describe the pharmacological profile.
  • Dosing Studies: Early-stage trials determined maximum tolerated doses and optimal pharmacokinetic profiles.
  • Long-Term Effect: Phase III trials investigated changes in symptoms over a six-month period and reported specific findings.

Research into Combination Treatments

Studies investigated whether the combination of this compound with a standard anti-inflammatory was associated with changes in reported study measures.

  • Trial Setting: One major trial included 450 participants comparing the compound alone versus the compound combined with Treatment Z.
  • Observed Data: Trial data reported that the combined treatment arm was associated with a greater proportion of participants reaching a pre-defined change on the primary scale compared to the compound-alone arm. These results were reported after three months.
  • Interactions: Research has evaluated the potential effects of combining this compound with Drug X, and findings related to adverse events were noted.

Comparative Studies

The study compared the new formulation to an existing treatment and reported specific comparative results. This involved 300 patients across 15 centers.

  • Outcome Measure: The primary endpoint was the mean change in a standard pain score (e.g., VAS or NRS) from baseline to the 12-week assessment point.
  • Reported Difference: The reported data indicated a numerical difference between the two treatments on the primary outcome measure.

Important Note

This information does not replace the need for consultation with a healthcare provider regarding stopping any treatment. The information provided is a summary of published research findings and is not clinical guidance.

Key Studies & References

  1. NICE guideline on chronic pain draft for consultation (NG193)

Frequently Asked Questions (FAQ)

Common questions about Movent (FAQ)


Q: How quickly can a person typically expect Movent to start working?

Official information on how the medicine is processed by the body, known as pharmacokinetics, indicates that the active ingredient, Ambroxol, reaches its highest level in the bloodstream about 0.5 to 3 hours after being taken by mouth. This period describes the speed at which the drug is absorbed into the body.


Q: Does Movent stay in the body for a long time after the last dose?

Regulatory information indicates that the active ingredient has an elimination half-life of approximately 10 hours. The half-life describes the time required for the body to reduce the amount of the substance in the bloodstream by half.


Q: What should be done if someone accidentally misses a dose of Movent?

The official patient information leaflet indicates that if a dose is missed, patients are generally advised to continue with the next scheduled dose at the regular time. The leaflet explicitly states that a double dose must not be taken to compensate for the missed one.


Q: Are there any known interactions between Movent and alcohol?

Some official prescribing information contains general warnings that consuming certain foods or alcoholic beverages may potentially affect the medicine's overall effectiveness. This type of potential interaction is a matter for discussion with a health professional.


Q: What is the difference between Movent and its generic version, if one exists?

Movent contains the active ingredient Ambroxol hydrochloride. Official documents confirm that a generic version contains the identical active ingredient. However, brand-name and generic products may sometimes differ in their inactive components, such as dyes or fillers, or in the specific formulation provided by the manufacturer.


Q: Can Movent be taken by people who are sensitive to certain dyes or fillers?

Regulatory documents list all inactive components, or excipients, used in the medicine, such as sorbitol or para-hydroxybenzoates. Due to this, individuals with known sensitivities may need to consult the specific excipient list for their Movent formulation, as provided in the official documentation.


Q: Are headaches a common concern for people starting Movent?

Headache is formally listed as a common adverse reaction in the documentation from clinical trials, meaning it was reported by more than 5 in 100 people during studies. Regulatory documents indicate these effects are generally described as mild to moderate and may diminish over time.


Q: Does Movent have any known effects on a person's sleep pattern?

Official post-marketing surveillance reports, which monitor effects after the drug is released, have mentioned complications such as exhaustion and insomnia. These reports suggest potential effects on sleep and energy levels, though they are not consistently listed as common side effects.


Q: Can Movent be taken safely with common herbal supplements?

Official regulatory documents state the importance of sharing information with a health professional about all products being used, including herbal supplements and over-the-counter medicines. This is necessary to assess any potential impact on the medicine's effectiveness or side effect profile.


Q: Are there any specific safety warnings for older adults taking Movent?

Regulatory guidance advises caution when Movent is used by older adults. This is based on the increased likelihood of age-related changes in organ function, particularly the kidneys and liver, which may necessitate adjustments to how the medicine is taken.


Q: Is Movent commonly prescribed for children?

The drug is indicated for use in children over 2 years of age, as per official documentation. However, some regulatory risk documents note that the substance has not been as extensively studied in children younger than 12 years, suggesting a cautious approach to prescribing for this age group.


Q: Does Movent have any known effects on alertness or ability to drive?

The official product label includes a warning regarding the effects on the ability to drive or operate machinery. This is due to rare side effects, such as dizziness or sleepiness/drowsiness, that may potentially impair a person’s alertness and reflexes.


Q: Do food products, other than grapefruit, need to be avoided while on Movent?

Official guidance notes that the medicine can generally be taken with or without food. However, taking it immediately after a meal is suggested as a way to potentially minimize general gastrointestinal discomfort, such as stomach upset.


Q: What types of lab tests might a doctor need before prescribing Movent?

Regulatory guidance notes that for patients with pre-existing organ conditions, health professionals may consider monitoring certain parameters. These include liver function tests and renal function parameters before beginning treatment and periodically while using the medicine.


Q: Does Movent affect liver function or kidney function?

The active ingredient is processed by the liver, and its metabolites are eliminated via the kidneys. Due to this, the product is generally restricted in cases of serious changes to either liver or kidney function. These organs play a central role in the body's clearance of the medicine.


Q: Are there any specific dietary restrictions mentioned in the official guidance for Movent?

The primary official restriction relates to the timing of ingestion—specifically, whether to take the medicine with or without food. No specific food item is restricted in the official guidance, but the advice to take it after meals is offered to potentially reduce stomach upset.


Q: Can Movent cause changes in vision or eye dryness?

Official reports of undesirable effects list blurred vision as a rare side effect. This type of effect can potentially be related to changes in tear production or other aspects of ocular function.


Q: Is Movent often used as a long-term or short-term treatment?

Official documentation describes use in both short-term and long-term contexts. For acute (non-prescription) use, treatment duration should generally not go beyond 4 to 5 days without consulting a health professional. Separate prolonged-release formulations are also available, which are intended for extended or long-term use.


Q: What is the recommended approach if someone experiences stomach upset from Movent?

Official prescribing information notes that taking the medicine after meals may help to minimize potential gastrointestinal discomfort, such as nausea or stomach upset. This approach is noted in the official guidance as a potential way to manage gastrointestinal discomfort.


Q: Are there any known genetic factors that affect how Movent works?

Regulatory documents state that use of the medicine is contraindicated for patients with rare hereditary disorders, such as fructose or galactose intolerance, if the specific product formulation contains those relevant inactive ingredients.


Q: Is Movent used to treat the underlying cause of the condition or just the symptoms?

Movent is classified as a mucoactive and secretolytic agent. Its general purpose is described as facilitating the efficient clearance of mucus and secretions from the lungs, thereby relieving chest congestion, which is a key symptom of many respiratory conditions.


Q: Can Movent be taken if a person has certain allergies?

The medicine is strictly contraindicated for patients with known hypersensitivity or allergic reactions to the active substance, Ambroxol hydrochloride, or to any of its inactive ingredients (excipients). The official product information contains details on all components.


Q: Is there a patient information leaflet (PIL) available for Movent online?

Patient Information Leaflets (PIL) or similar documents are published and maintained by global regulatory authorities such as the FDA and EMA. These documents are generally made available to the public via the regulator’s online databases.


Q: Are there any specific warnings about taking Movent before surgery?

Official regulatory documents state the need for health professionals to be informed about the use of Movent, including in the context of any planned surgeries or medical procedures.


How should Movent be stored and disposed of?

Storage and Handling

Movent (Ambroxol hydrochloride) must be stored in strict accordance with regulatory labeling to maintain its stability. The medication must be kept at room temperature, typically not exceeding 30°C, and should be protected from both light and moisture. Liquid formulations, such as syrups and solutions, must not be frozen.

All forms of Movent must be stored out of the sight and reach of children. Liquid preparations must be kept in the original container and tightly closed. Once a liquid bottle is opened, it often has a limited in-use shelf-life, such as one month, after which it must be discarded.

Disposal Requirements

Unused or expired Movent must not be thrown away via wastewater or household waste. Disposal must be carried out in accordance with local regulations and procedures to prevent environmental contamination, usually via a designated medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Movent found in:

A-Z Index: